phrykt

Zenas BioPharma, Inc. (ZBIO): who owns it and who trades it

As of Nov 16, 2026, ZBIO insiders reported 17 purchases worth $11.4M in the last 12 months. The largest buyer was Leon O Moulder Jr (CEO), with $5.8M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Zenas BioPharma

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ZBIO

146 funds and institutions reported ZBIO shares worth $1.6B at the end of Q2 2026, about 99% of the company. The largest holder is FMR LLC (Fidelity) with 15.1%.

Funds and institutions (13F) 99%Everyone else 1%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.1%
SR One Capital Management, LP8.0%
NEA Management Company, LLC6.4%
Enavate Sciences Gp, LLC6.2%
Federated Hermes, Inc.4.9%
BlackRock, Inc.4.3%
Capital International Investors4.0%
Polar Capital Holdings Plc3.8%
Royalty Pharma Sub-Manager, LLC3.8%
Fairmount Funds Management LLC3.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)9.51M15.06%$241M+5%
SR One Capital Management, LP5.04M7.98%$128MNo change
NEA Management Company, LLC4.02M6.37%$102MNo change
Enavate Sciences Gp, LLC3.92M6.21%$99.5MNo change
Federated Hermes, Inc.3.12M4.94%$79.1M-0%
BlackRock, Inc.2.69M4.25%$68.2M+32%
Capital International Investors2.50M3.96%$63.5M+3%
Polar Capital Holdings Plc2.41M3.82%$61.2M-5%
Royalty Pharma Sub-Manager, LLC2.39M3.78%$60.6M–
Fairmount Funds Management LLC2.36M3.74%$59.9MNo change
State Street Corp2.06M3.26%$52.2M+40%
Nvp Associates, LLC1.84M2.91%$46.7MNo change
Wellington Management Group LLP1.59M2.52%$40.5M+28%
Vanguard Capital Management LLC1.35M2.15%$34.4M+9%
Bank of America Corp1.23M1.95%$31.2M+217%
T. Rowe Price Associates1.23M1.94%$31.1M+243%
Alliancebernstein L.P.1.10M1.75%$21.6M+23%
Geode Capital Management, LLC882,6541.40%$22.4M+35%
Two Sigma Investments, LP815,1501.29%$20.7M+196%
EcoR1 Capital, LLC789,5001.25%$20MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ZBIO insiders reported $11.4M of open-market purchases and $0 of sales.

Purchases, 12 months
$11.4M
17 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
May 18, 2026
Filed May 18, 2026

Purchases and sales by month

$5.6M$5.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 18, 2026Leon O Moulder JrCEOPurchase60,000$16.88$1MForm 4
Apr 29, 2026Leon O Moulder JrCEOPurchase35,000$17.62$617KForm 4
Apr 28, 2026Leon O Moulder JrCEOPurchase25,000$18.02$450KForm 4
Mar 31, 2026Hongbo LuDirectorPurchase3,768$18.63$70.2KForm 4
Mar 31, 2026Tomas Kiselak +3DirectorPurchase150,000$20.00$3MForm 4
Mar 31, 2026Leon O Moulder JrCEOPurchase34,000$19.31$657KForm 4
Mar 31, 2026Hongbo LuDirectorPurchase75,000$20.00$1.5MForm 4
Mar 30, 2026Leon O Moulder JrCEOPurchase20,000$18.23$365KForm 4
Feb 13, 2026Patricia L AllenDirectorPurchase4,160$26.36$110KForm 4
Feb 12, 2026Patricia L AllenDirectorPurchase5,700$24.34$139KForm 4
Feb 12, 2026Patricia L AllenDirectorPurchase5,000$23.77$119KForm 4
Feb 12, 2026Patricia L AllenDirectorPurchase5,000$26.50$132KForm 4
Feb 11, 2026Hongbo LuDirectorPurchase25,985$22.50$585KForm 4
Feb 2, 2026Leon O Moulder JrCEOPurchase57,000$17.96$1MForm 4
Jan 9, 2026Leon O Moulder JrCEOPurchase20,000$16.55$331KForm 4
Jan 8, 2026Leon O Moulder JrCEOPurchase30,000$16.30$489KForm 4
Jan 7, 2026Leon O Moulder JrCEOPurchase50,000$16.38$819KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Leon O Moulder JrChief Executive Officer, Director$5.8M–May 18, 2026
Tomas KiselakDirector$3M–Mar 31, 2026
Hongbo LuDirector$2.2M–Mar 31, 2026
Patricia L AllenDirector$500K–Feb 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ZBIO short interest

High short interest. 16.7% of ZBIO shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.35M ZBIO shares were sold short, 16.7% of the shares outstanding, down 9.4% from the report before. At the average daily volume of 471,475 shares, buying them all back would take about 24.1 trading days (days to cover).

Shares short, % of all shares

16.7%May 15Oct 3019.7%

Days to cover

24.1May 15Oct 3026.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.35M16.74%-9%471,47524.1
Oct 15, 202612.54M19.24%+5%666,05818.8
Sep 30, 202611.94M18.32%+1%771,65315.5
Sep 15, 202611.87M18.21%+1%529,25122.4
Aug 31, 202611.70M17.95%+0%825,02314.2
Aug 14, 202611.66M17.89%-1%553,67021.1
Jul 31, 202611.75M18.03%-3%850,07613.8
Jul 15, 202612.17M19.28%-0%976,88012.5
Jun 30, 202612.20M19.32%+10%1.26M9.6
Jun 15, 202611.13M17.63%+2%575,80219.3
May 29, 202610.88M17.23%+2%599,92218.1
May 15, 202610.69M16.93%-2%501,40521.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Zenas BioPharma company events

Zenas BioPharma filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AnnouncementAs previously disclosed, on October 8, 2025, Zenas BioPharma, Inc. entered into a Sales Agreement with Jefferies LLC, with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value… Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Oct 13, 2026AnnouncementShared information with investors. Filing
  4. Aug 13, 2026LeadershipAppointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors, on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting… Filing
  5. May 13, 2026LeadershipZenas BioPharma, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  6. Mar 31, 2026AgreementZenas BioPharma, Inc. completed its public offering of $200 million of its 2.50% Convertible Senior Notes due 2032. Filing
  7. Mar 16, 2026ResultsReleased financial results. Filing
  8. Feb 13, 2026LeadershipThe Board of Directors of Zenas BioPharma, Inc. approved the Company’s Amended and Restated Short-Term Incentive Plan, effective as of January 1, 2026. Filing
  9. Jan 5, 2026AnnouncementThe Company announced positive results from the INDIGO trial. Filing
  10. Dec 15, 2025LeadershipThe Board approved the Zenas BioPharma, Inc. 2026 Inducement Plan, the form of Non-Statutory Stock Option Agreement under the 2026 Inducement Plan, the form of Global Non-Statutory Stock Option Agreement under the 2026 Inducement Plan, the form of Restricted Stock Unit Agreement under the 2026… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Zenas BioPharma financials

Famous investors that hold ZBIO

3 of the 50 well-known investors we track reported holding ZBIO in their latest 13F filing. The largest position is Israel Englander's, worth $5.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026194,052$5.2M0.0%-71%
Steve Cohen · Point72 Asset ManagementQ3 202698,787$2.7M0.0%+512%
Paul Tudor Jones · Tudor Investment CorpQ3 202616,907$456K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ZBIO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G/A12.4%
Nov 16, 2026Wellington Management Group LLP13G/A12.4%
Oct 27, 2026BlackRock, Inc.13G5.0%
Oct 27, 2026BlackRock, Inc.13G5.0%

Questions about Zenas BioPharma, Inc. (ZBIO) stock

Who owns the most ZBIO stock?

The largest reported owner of Zenas BioPharma, Inc. (ZBIO) is FMR LLC (Fidelity), with 15.1% of the company. In total, 146 funds and institutions reported holding ZBIO at the end of Q2 2026, together about 99% of the shares. See the largest owners.

Are ZBIO insiders buying or selling?

In the last 12 months, ZBIO insiders reported 17 open-market purchases worth $11.4M and no sales. The latest trade was on May 18, 2026. See every trade.

What is the short interest in ZBIO?

As of Oct 30, 2026, 11.35M ZBIO shares were sold short, 16.7% of the shares outstanding, down 9.4% from the report before. At the average daily volume of 471,475 shares, buying them all back would take about 24.1 trading days (days to cover). See the history.

Which famous investors hold ZBIO?

3 of the 50 well-known investors we track reported ZBIO in their latest 13F filing, including Israel Englander, Steve Cohen, Paul Tudor Jones. The largest position is worth $5.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.